Skip to main content Skip to navigation
Hamburger Menu
Search icon
Country Selector Country Selector
China (Chinese)
Profile Icon Profile Icon
登录/注册 UserName
产品

解决方案

发现&学习

资源&工具

Support

Search icon Search icon
Close Menu
      Alert Icon
      BUV737 Biosimilar Anti-Human CD52

      BD OptiBuild™ BUV737 Biosimilar Anti-Human CD52

      克隆 Alemtuzumab297.rMAb (also known as Alemtuzumab N297A Biosimilar.rMAb)

      (RUO)
      查看所有格式
      商品详情
      Down Arrow Up Arrow


      BD OptiBuild™
      CAMPATH-1 antigen; HE5
      Human (Tested in Development)
      Human IgG1, κ
      Human CD52
      Flow cytometry (Qualified)
      0.2 mg/ml
      1043
      Aqueous buffered solution containing ≤0.09% sodium azide.
      RUO


      准备和存储

      The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated to the dye under optimum conditions that minimize unconjugated dye and antibody. Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze.
      显示较多信息 blue down arrow 显示较少信息 blue up arrow

      推荐的实验流程

      BD® CompBeads can be used as surrogates to assess fluorescence spillover (compensation).  When fluorochrome conjugated antibodies are bound to BD® CompBeads, they have spectral properties very similar to cells.   However, for some fluorochromes there can be small differences in spectral emissions compared to cells, resulting in spillover values that differ when compared to biological controls.  It is strongly recommended that when using a reagent for the first time, users compare the spillover on cells and BD® CompBeads to ensure that BD® CompBeads are appropriate for your specific cellular application.

      For optimal and reproducible results, BD Horizon Brilliant™ Stain Buffer should be used anytime BD Horizon Brilliant dyes are used in a multicolor flow cytometry panel.  Fluorescent dye interactions may cause staining artifacts which may affect data interpretation.  The BD Horizon Brilliant Stain Buffer was designed to minimize these interactions. When BD Horizon Brilliant Stain Buffer is used in in the multicolor panel, it should also be used in the corresponding compensation controls for all dyes to achieve the most accurate compensation. For the most accurate compensation, compensation controls created with either cells or beads should be exposed to BD Horizon Brilliant Stain Buffer for the same length of time as the corresponding multicolor panel. More information can be found in the Technical Data Sheet of the BD Horizon Brilliant Stain Buffer (Cat. No. 563794/566349) or the BD Horizon Brilliant Stain Buffer Plus (Cat. No. 566385).

      Note:  When using high concentrations of antibody, background binding of this dye to erythroid cell subsets (mature erythrocytes and precursors) has been observed.  For researchers studying these cell populations, or in cases where light scatter gating does not adequately exclude these cells from the analysis, this background may be an important factor to consider when selecting reagents for panel(s).

      显示较多信息 blue down arrow 显示较少信息 blue up arrow

      商品通知

      1. The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
      2. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
      3. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
      4. An isotype control should be used at the same concentration as the antibody of interest.
      5. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
      6. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
      7. Human donor specific background has been observed in relation to the presence of anti-polyethylene glycol (PEG) antibodies, developed as a result of certain vaccines containing PEG, including some COVID-19 vaccines. We recommend use of BD Horizon Brilliant™ Stain Buffer in your experiments to help mitigate potential background. For more information visit https://www.bdbiosciences.com/en-us/support/product-notices.
      8. Please refer to http://regdocs.bd.com to access safety data sheets (SDS).
      9. For U.S. patents that may apply, see bd.com/patents.
      显示较多信息 blue down arrow 显示较少信息 blue up arrow
      758157 Rev. 1
      抗体详情
      Down Arrow Up Arrow
      Alemtuzumab297.rMAb

      The Alemtuzumab297.rMAb  (also known as, Alemtuzumab N297A Biosimilar.rMAb) is a research grade humanized recombinant human IgG1, kappa antibody that specifically recognizes the extracellular domain of human CD52, similarly to the therapeutic Alemtuzumab antibody. The Alemtuzumab297.rMAb uses variable region sequences from Alemtuzumab and constant region consensus sequences from human IgG1 kappa. The asparagine at position 297 of the constant heavy chain has been replaced with alanine (N297A) to further reduce Fc receptor interactions.  The CD52 antigen is a 25-29 kDa N-glycosylated, GPI-linked protein that is also known as Cambridge pathology antigen 1 (CAMPATH-1 antigen), or Human epididymis-specific protein 5 (He5).  It is expressed on thymocytes, lymphocytes, monocytes, macrophages, dendritic cells, and eosinophils, but is weakly or not expressed on neutrophils, erythrocytes, platelets, or hematopoietic stem cells. CD52 is variably expressed on malignant lymphoid cells and serves as a target for therapeutic CD52-specific antibodies.

      The Alemtuzumab297.rMAb is intended for research use only. It is not intended for use in therapeutic or diagnostic procedures for humans or animals.

      758157 Rev. 1
      格式详情
      Down Arrow Up Arrow
      BUV737
      The BD Horizon Brilliant™ Ultraviolet 737 (BUV737) Dye is part of the BD Horizon Brilliant™ Ultraviolet family of dyes. This tandem fluorochrome is comprised of a BUV395 donor with an excitation maximum (Ex Max) of 350-nm and an acceptor dye with an emission maximum (Em Max) at 735-nm. BUV737, driven by BD innovation, is designed to be excited by the ultraviolet laser (355-nm) and detected using an optical filter centered near 740-nm (e.g., 740/35 bandpass filter). The acceptor dye can be excited by the Red (628–640nm) laser resulting in cross-laser excitation and fluorescence spillover. Please ensure that your instrument’s configurations (lasers and optical filters) are appropriate for this dye.
      altImg
      BUV737
      Ultraviolet 355 nm
      350 nm
      735 nm
      758157 Rev.1
      报价单和参考
      Down Arrow Up Arrow
      View product citations for antibody "758157" on CiteAb

      研发参考 (10)

      1. Bologna L, Gotti E, Manganini M, et al. Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab.. J Immunol. 2011; 186(6):3762-9. (Biology). 查看参考
      2. Golay J, Manganini M, Rambaldi A, Introna M. Effect of alemtuzumab on neoplastic B cells.. Haematologica. 2004; 89(12):1476-83. (Biology). 查看参考
      3. Hale G. Synthetic peptide mimotope of the CAMPATH-1 (CD52) antigen, a small glycosylphosphatidylinositol-anchored glycoprotein.. Immunotechnology. 1995; 1(3-4):175-87. (Biology). 查看参考
      4. Havari E, Turner MJ, Campos-Rivera J, et al. Impact of alemtuzumab treatment on the survival and function of human regulatory T cells in vitro.. Immunology. 2014; 141(1):123-31. (Biology). 查看参考
      5. Lowenstein H, Shah A, Chant A, Khan A. Different mechanisms of Campath-1H-mediated depletion for CD4 and CD8 T cells in peripheral blood.. Transpl Int. 2006; 19(11):927-36. (Biology). 查看参考
      6. Mohan SR, Clemente MJ, Afable M, et al. Therapeutic implications of variable expression of CD52 on clonal cytotoxic T cells in CD8+ large granular lymphocyte leukemia.. Haematologica. 2009; 94(10):1407-14. (Biology). 查看参考
      7. Pernick N. CD50-59. 2023. Available: https://www.pathologyoutlines.com/topic/cdmarkerscd50.html 10/162023.
      8. Riechmann V, van Crüchten I, Sablitzky F. The expression pattern of Id4, a novel dominant negative helix-loop-helix protein, is distinct from Id1, Id2 and Id3. Nucleic Acids Res. 1994; 22(5):749-755. (Biology). 查看参考
      9. Toh BH, Kyaw T, Tipping P, Bobik A. Immune regulation by CD52-expressing CD4 T cells.. Cell Mol Immunol. 2013; 10(5):379-82. (Biology). 查看参考
      10. Trzonkowski P, Zilvetti M, Friend P, Wood KJ. Recipient memory-like lymphocytes remain unresponsive to graft antigens after CAMPATH-1H induction with reduced maintenance immunosuppression.. Transplantation. 2006; 82(10):1342-51. (Biology). 查看参考
      查看所有文件 (10) 查看更少内容
      758157 Rev. 1

       

      Please refer to Support Documents for Quality Certificates


      Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described


      Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims.  Comparisons are not made against non-BD technologies, unless otherwise noted.

      For Research Use Only. Not for use in diagnostic or therapeutic procedures.